2026 ESMO丨全新一代KRAS G12C抑制剂：Divarasib以III期头对头全面获益，彰显KRAS G12C突变NSCLC后线治疗同类最佳潜力_腾讯新闻
前言在近期落幕的2026年欧洲肿瘤内科学会（ESMO）年会上，III期Krasce...
New Standard-of-Care for KRAS G12C-Mutated Advanced NSCLC
Credit: Mohammed Haneefa Nizamudeen/Getty Images The next-generation, oral KRAS G12C inhibitor divarasib significantly reduces the risk for disease progression or death compared with existing KRAS-targeted treatments in patients with previously treated KRAS G12C-mutated advanced or metastatic non-small-cell lung cancer (NSCLC),...
How Does Divarasib Compare With Other KRAS Inhibitors in NSCLC?
Divarasib’s ORR was 58% vs 32% for sotorasib or adagrasib in the phase 3 Krascendo 1 trial. Dr Skoulidis discusses response, durability, and survival In this video interview, Ferdinandos Skoulidis, MD, PhD, highlights the importance of these efficacy findings, particularly...
Dr Skoulidis on Emerging KRAS Inhibitors in NSCLC
Ferdinandos Skoulidis, MD, PhD, explores emerging KRAS-targeted therapies in KRAS-mutated non–small cell lung cancer Skoulidis,a professor of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, described divarasib as a best-in-class inactive-state-selective KRAS G12C inhibitor....
Sotorasib (Lumakras; AMG 510): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in KRAS G12C-Mutated Lung and Colorectal Cancer
Sotorasib (Lumakras; AMG 510): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in KRAS G12C-Mutated Lung and Colorectal Cancer Key takeaways Sotorasib is an oral, irreversible KRAS G12C inhibitor. It was the first KRAS-targeted therapy approved by the FDA. It...
ESMO 2026: New targeted therapy improved survival for patients with KRAS-mutated lung cancer
Patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) lived significantly longer and saw improved disease control when treated with the next-generation KRAS targeted therapy divarasib, according to researchers from The University of Texas MD Anderson Cancer...
Krascendo 1 Survival Data Position Divarasib to Reset Second-Line Standards and Fuel First-Line Combinations in KRAS G12C–Mutated NSCLC
Krascendo 1 Survival Data Position Divarasib to Reset Second-Line Standards and Fuel First-Line Combinations in KRAS G12C–Mutated NSCLC The phase 3 Krascendo 1 trial (NCT06497556) showed that divarasib improved progression-free survival (PFS) and overall survival (OS) compared with sotorasib (Lumakras)...